Phaseline

Targets › LMP2

LMP2 (Proteasome subunit beta type-9): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Mar 2027.

The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity. This subunit is involved in antigen processing to generate class I binding peptides. (UniProt, P28065)

Open in Phaseline: the race on LMP2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Baylor College of MedicineEBV-specific T cells: A (LMP, BARF1 and EBNA1 specific CTLs)
EBV-specific cytotoxic T lymphocytes targeting viral antigens LMP1, LMP2, BARF1, and EBNA1
LMP1, LMP2, BARF1, EBNA1Phase 1Hodgkin's DiseaseMar 2027

Conditions

Hodgkin's Disease (1)

Modalities

other (1)

Companies

Baylor College of Medicine (1)

Related targets

LMP1 (1) BARF1 (1) EBNA1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.